Mathematical Modeling Analysis of Serum Prostate Specific Antigen After Radiotherapy
This study has been completed.
Information provided by (Responsible Party):
AHS Cancer Control Alberta ( Alberta Health Services )
First received: August 3, 2005
Last updated: December 8, 2011
Last verified: December 2011
Clinical data are being used to build a mathematical model to describe the clinical results of radiotherapy for prostate cancer.
||Observational Model: Case-Only
Time Perspective: Retrospective
||Mathematical Modeling Analysis of Serum Prostate Specific Antigen After Radiotherapy
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||March 2008 (Final data collection date for primary outcome measure)
Clinical data (prostate-specific antigen [PSA] response after radiotherapy) are being used to build a mathematical model to describe the clinical results of radiotherapy for prostate cancer.
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Prostate cancer treated with radiotherapy +/- hormones
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00126815
|Cross Cancer Institute
|Edmonton, Alberta, Canada, T6G 1Z2 |
Alberta Health Services
||Matthew Parliament, MD
||AHS Cancer Control Alberta
No publications provided
||AHS Cancer Control Alberta ( Alberta Health Services )
History of Changes
|Other Study ID Numbers:
|Study First Received:
||August 3, 2005
||December 8, 2011
||Canada: Health Canada
Keywords provided by AHS Cancer Control Alberta:
prostate specific antigen
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on August 31, 2015
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms by Site